

## 略歴書（②再生医療等）

古賀 祥嗣 ※再生医療の専門家

社会福祉法人 仁生社 江戸川病院副院長

免許

医師免許証 第 328079 号

学位

医学博士 東京女子医科大学乙号 2 1 8 7 号

1989年3月	産業医科大学医学部卒業
1989年5月	東京女子医科大学第3外科学教室（太田和夫教授）臨床研修医
1989年10月	済生会川口病院泌尿器科
1991年4月	南大和病院外科
1992年4月	川島病院透析科
1993年1月	和歌山赤十字病院泌尿器科
1995年4月	東京女子医科大学泌尿器科助手（東間紘教授）として帰局
1996年11月	米国オハイオ州クリーブランドクリニックに留学（移植免疫と遺伝子治療の研究）
1999年8月	帰国し、東京女子医科大学泌尿器科助手
2001年2月	西新井病院腎センター長および泌尿器科部長
2003年2月	東京医科大学 泌尿器科学教室 講師
2005年9月	東京西徳洲会病院 腎臓病総合医療センター長
2009年9月	社会福祉法人仁生社江戸川病院 腎移植、透析センター統括センター長兼泌尿器科主任部長
2021年4月	社会福祉法人仁生社江戸川病院副院長 ソラリアクリニック東京・管理者就任

所属学会

日本泌尿器科学会

日本透析医学会

日本移植学会

日本臨床腎移植学会

日本癌治療学会

日本腹膜透析学会

日本泌尿器内視鏡学会

日本再生医療学会

#### 専門医

日本泌尿器科学会専門医 (第94018111号)

日本泌尿器科学会指導医 (第99007221号)

日本透析医学会専門医 (第3584号)

日本透析医学会指導医

日本移植学会専門医

日本再生医療学会再生医療認定医

#### 近年の再生医療関連の活動

PC3210004 Alpha-Galactosylceramide 刺激自己樹状細胞を用いた NKT 細胞標的治療 (RIKNKT) 皮下投与

PC3210005 Alpha-Galactosylceramide 刺激自己樹状細胞を用いた NKT 細胞標的治療 (RIKNKT) 点滴静脈注射

#### 論文

1: Kobayashi H, **Koga S**, Novick AC, Toma H, Fairchild RL.

T-cell mediated induction of allogeneic endothelial cell chemokine expression. Transplantation. 2003 Feb 27;75(4):529-36.

2: Komata T, Kondo Y, Kanzawa T, Ito H, Hirohata S, **Koga S**, Sumiyoshi H, Takakura M, Inoue M, Barna BP, Germano IM, Kyo S, Kondo S.

Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. Hum Gene Ther. 2002 Jun10;13(9):1015-25.

3: Komata T, **Koga S**, Hirohata S, Takakura M, Germano IM, Inoue M, Kyo S, Kondo S, Kondo Y. A novel treatment of human malignant gliomas in vitro and in vivo: FADD genetransfer under the control of the human telomerase reverse transcriptase genepromoter. Int J Oncol. 2001 Nov;19(5):1015-20.

4: **Koga S**, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, Kyo S, Kondo S. FADD gene therapy using the human telomerase catalytic subunit (hTERT) genepromoter to restrict induction of apoptosis to tumors in vitro and in vivo. Anticancer Res. 2001 May-Jun;21(3B):1937-43.

5: Komata T, Kondo Y, Kanzawa T, Hirohata S, **Koga S**, Sumiyoshi H, Srinivasula SM,

Barna BP, Germano IM, Takakura M, Inoue M, Alnemri ES, Shay JW, Kyo S, Kondo S. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. *Cancer Res.* 2001 Aug 1;61(15):5796-802.

6: **Koga S**, Kondo Y, Komata T, Kondo S. Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA. *Gene Ther.* 2001 Apr;8(8):654-8.

7: Komata T, Kondo Y, **Koga S**, Ko SC, Chung LW, Kondo S. Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53. *Gene Ther.* 2000 Dec;7(24):2071-9.

8: Mukai S, Kondo Y, **Koga S**, Komata T, Barna BP, Kondo S. 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. *Cancer Res.* 2000 Aug 15;60(16):4461-7.

9: **Koga S**, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, Kyo S, Kondo S. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. *Hum Gene Ther.* 2000 Jul 1;11(10):1397-406.

10: Kondo Y, **Koga S**, Komata T, Kondo S. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. *Oncogene.* 2000 Apr 27;19(18):2205-11.

11: **Koga S**, Kobayashi H, Novick AC, Toma H, Fairchild RL. Prolonged class II MHC disparate skin allograft survival by treatment with antibodies to the chemokine Mig. *Transplant Proc.* 2001 Feb-Mar;33(1-2):549-50.

12: **Koga S**, Kobayashi H, Novick AC, Toma H, Fairchild RL. Alloantigen-specific CD8(+) T cells stimulate endothelial cells to produce the T-cell chemoattractants IP-10 and Mig. *Transplant Proc.* 2001 Feb-Mar;33(1-2):459-60.

13: **Koga S**, Kapoor A, Novick AC, Toma H, Fairchild RL. RANTES is produced by CD8+ T cells during acute rejection of skin grafts. *Transplant Proc.* 2000 Jun;32(4):796-7. No abstract available.

14: Watarai Y, **Koga S**, Paolone DR, Engeman TM, Tannenbaum C, Hamilton TA, Fairchild RL. Intraallograft chemokine RNA and protein during rejection of MHC-matched/multiple minor histocompatibility-disparate skin grafts. *J Immunol.* 2000 Jun 1;164(11):6027-33.

15: Kapoor A, Morita K, Engeman TM, **Koga S**, Vapnek EM, Hobart MG, Fairchild RL. Early expression of interferon-gamma inducible protein 10 and monokine induced by interferon-gamma in cardiac allografts is mediated by CD8+ T cells. *Transplantation.* 2000 Mar 27;69(6):1147-55.

- 16: **Koga S**, Auerbach MB, Engeman TM, Novick AC, Toma H, Fairchild RL. T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-gamma-induced chemokine Mig. *J Immunol*. 1999 Nov 1;163(9):4878-85.
- 17: **Koga S**, Novick AC, Toma H, Fairchild RL. CD8+ T cells produce RANTES during acute rejection of murine allogeneic skin grafts. *Transplantation*. 1999 Mar 27;67(6):854-64.
- 18: Shimizu T, Tanabe K, Tokumoto T, Shimmura H, **Koga S**, Ishikawa N, Oshima T, Toma H, Yamaguchi Y. A case of rapid progressive glomerulonephritis with IgA deposits after renal transplantation. *Clin Transplant*. 2001;15 Suppl 5:11-5.
- 19: **Koga S**, Luke PP, Specht SM, Rominski B, Jaquins-Gerstl A, Hoffman RA, Thomson AW, Jordan ML. Inhibition of the allograft response by donor specific blood transfusion: association with reduced local TH1 cytokines and nitric oxide but enhanced prostaglandin E2 production. *Transplantation*. 2000 Dec 27;70(12):1788-96.
- 20: Toda F, Tanabe K, Tokumoto T, Ishikawa N, **Koga S**, Ito S, Yagisawa T, Toma H. Non-heart-beating donor kidney transplantation under tacrolimus immunosuppression. *Transplant Proc*. 2000 Nov;32(7):1726-9.
- 21: Tanabe K, Tokumoto T, Ishikawa N, Shimizu T, Okuda H, Ito S, Shinmura H, Inui M, Harano M, Manu M, **Koga S**, Shiroyanagi Y, Goya N, Yagisawa T, Fuchinoue S, Toma H. Malabsorption of tacrolimus in kidney transplant recipients: a Japanese single center experience. *Transplant Proc*. 2000 Nov;32(7):1718-20.
- 22: Tanabe K, Tokumoto T, Ishikawa N, Shimizu T, Okuda H, Ito S, Shimmura H, Inui M, Harano M, Manu M, **Koga S**, Ohtsubo S, Suzuki K, Shiroyanagi Y, Goya N, Nakazawa H, Yagisawa T, Nakajima I, Fuchinoue S, Toma H. Japanese single-center experience of kidney transplantation under tacrolimus immunosuppression. *Transplant Proc*. 2000 Nov;32(7):1696-9.
- 23: Toda F, Tanabe K, Ishikawa N, Tokumoto T, Ito S, **Koga S**, Yagisawa T, Toma H. Kidney transplantation from living donors with renal artery disease. *Transplant Proc*. 2000 Nov;32(7):1591-2.
- 24: Tanabe K, Oshima T, Tokumoto T, Ishikawa N, Kanematsu A, Shinmura H, **Koga S**, Fuchinoue S, Takahashi K, Toma H. Long-term renal function in on-heart-beating donor kidney transplantation: a single-center experience. *Transplantation*. 1998 Dec 27;66(12):1708-13.
- 25: Ishikawa N, Tanabe K, Tokumoto T, **Koga S**, Okuda H, Nakazawa H, Takahashi K, Toma H. Renal cell carcinoma of native kidneys in renal transplant recipients. *Transplant Proc*. 1998 Nov;30(7):3156-8.

- 26: Tanabe K, Takahashi K, Sonda K, Tokumoto T, Ishikawa N, Kawai T, Fuchinoue S, Oshima T, Yagisawa T, Nakazawa H, Goya N, **Koga S**, Kawaguchi H, Ito K, Toma H, Agishi T, Ota K. Long-term results of ABO-incompatible living kidney transplantation: a single-center experience. *Transplantation*. 1998 Jan 27;65(2):224-8.
- 27: Tanabe K, Tokumoto T, Ishikawa N, Koyama I, Takahashi K, Fuchinoue S, Kawai T, **Koga S**, Yagisawa T, Toma H, Ota K, Nakajima H. Comparative study of cytomegalovirus (CMV) antigenemia assay, polymerase chain reaction, serology, and shell vial assay in the early diagnosis and monitoring of CMV infection after renal transplantation. *Transplantation*. 1997 Dec 27;64(12):1721-5.
- 28: Tanabe K, Kobayashi C, Takahashi K, Sonda K, Tokumoto T, Ishikawa N, **Koga S**, Naito T, Kawai T, Fuchinoue S, Yagisawa T, Goya N, Nakazawa H, Kawaguchi H, Ito K, Agishi T, Toma H, Ota K. Long-term renal function after pregnancy in renal transplant recipients. *Transplant Proc*. 1997 Feb-Mar;29(1-2):1567-8.
- 29: Kawai T, Sachs DH, Hoshino T, **Koga S**, Tanabe K, Toma H, Ota K, Colvin RB, Cosimi AB. Graft-vs-host tolerance in mixed allogeneic chimerism. *Transplant Proc*. 1997 Feb-Mar;29(1-2):1222-3.
- 30: Tanabe K, Takahashi K, Koyama I, Sonda K, Fuchinoue S, Kawai T, Tokumoto T, **Koga S**, Naito T, Yagisawa T, Toma H, Ota K, Nakajima H. Early diagnosis of CMV syndrome after kidney transplantation: comparison between CMV antigenemia and PCR assay. *Transplant Proc*. 1996 Jun;28(3):1508-10.
- 31: Tokumoto T, Tanabe K, Sonda K, **Koga S**, Gouya N, Yagisawa T, Nakazawa H, Kawai T, Fuchinoue S, Teraoka S, Takahashi K, Toma H, Ota K. Effect of interferon (IFN-alpha) for prevention of hepatitis C transmission from a seropositive donor to a seronegative recipient in renal transplantation. *Transplant Proc*. 1996 Jun;28(3):1503-4.
- 32: **Koga S**, Tanabe K, Yagisawa TT, Toma H. Urological complications in renal transplantation. *Transplant Proc*. 1996 Jun;28(3):1472-3.
- 33: Tanabe K, Takahashi K, Sonda K, Onituka S, Yamaguchi Y, Agishi T, **Koga S**, Koga T, Nakazawa H, Goya N, Yagisawa T, Fuchinoue S, Kawai T, Toma H, Ota K. Clinicopathological analysis of rejection episodes in ABO-incompatible kidney transplantation. *Transplant Proc*. 1996 Jun;28(3):1447-8.
- 34: Tanabe K, Takahashi K, Sonda K, Tokumoto T, **Koga S**, Nakazawa H, Goya N, Yagisawa T, Fuchinoue S, Kawai T, Toma H, Ota K. Long-term results of OKT3-treated renal transplant recipients. *Transplant Proc*. 1996 Jun;28(3):1350-118:

35: Tanabe K, **Koga S**, Takahashi K, Sonda K, Tokumoto T, Babazono T, Yagisawa T, Toma H, Kawai T, Fuchinoue S, Teraoka S, Ota K.

Diabetes mellitus after renal transplantation under FK 506 (tacrolimus) as primary immunosuppression. *Transplant Proc.* 1996 Jun;28(3):1304-5.

36: Hayashi T, **Koga S**, Higashi Y, Ohtomo Y, Satomura K, Mannami M.

Living-related renal transplantation from elderly donors (older than 66 years of age). *Transplant Proc.* 1995 Feb;27(1):984-5.